Skip to main content

Table 1 Main characteristics of included RCTs

From: Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study

Study Sample size (n) Diagnosis TRD definition Medication regimen rTMS parameters Outcome assessment Follow-up? Adverse effects
  rTMS sham     Frequency,Hz Intensity (%MT) Sessions Total pulses    
Garcia-Toro et al. [36] 17 18 DSM-IV MDD Failed 2 or more ADs, 6 weeks minimum continue current treatment 20 90 10 12000 HAMD-21 2w of an open trial Scalp discomfort and slight headaches
Rossini et al. [38] 18 17 DSM-IV MDD & ≥ 26 in HAMD-21 Failed 2 or more ADs, 6 weeks minimum continue current treatment 15 100 10 6000 HAMD-21 3w of follow up Mild headache; discomfort at the site of stimulation
19      15 80   6000    
Garcia-Toro et al. [37] 10 10 DSM-IV MDD Failed 2 or more ADs, 1 month minimum continue current treatment 20,1 110 10 12000 HAMD-21 2w of follow up Scalp discomfort and headaches
10      20,1 110   12000    
Bretlau et al. [27] 22 23 DSM-IV MDD Failed 2 or more ADs, 6 weeks minimum Escitalopram from 10 mg/d to 20 mg/d 8 90 15 19200 HAMD-17 9w of follow up Reduced sleep length and greater concentration difficulties (sham group)
Martinot et al. [39] 16 14 DSM-IV-R MDD& ≥18 in MADRS & ≥16 in HAMD Failed 2 or more ADs, 4 weeks minimum minimal and stable dosage of previous treatment 10 90 10 16000 HAMD-21 N Not mentioned
18      10 90   16000    
Bakim et al. [30] 12 12 DSM-IV MDD & ≥18 in MADRS & ≥20 in HAMD Failed 2 or more ADs, 6 weeks minimum continue current treatment 20 80 30 24000 HAMD-17 N Mild headache and mild discomfort
11      20 100   24000    
Chen et al. [35] 10 11 DSM-IV MDD & ≥ 18 in HAMD-17 Failed 2 or more ADs, 6 weeks minimum continue current treatment, stable dose 20 90 10 8000 HAMD-17 9w of follow up Not mentioned(1 dropouts for unspecific somatic complaints, sham group)